The Food and Drug Administration have approved a combination drug named Lonsurf for the people suffering from metastatic gastric adenocarcinoma.
The report was published on the official website of U.S Food and Drug Administration.
Gastric adenocarcinoma is a type of stomach cancer and it is said to be the second most common cancer in the world. According to the reports, the combo drug of Lonsurf can cure those patients who are suffering from gastric adenocarcinoma or gastric junction.
The new drug is the combination of trifluridine, tipiracil, a nucleoside metabolic inhibitor, and a thymidine phosphorylase inhibitor. This dose will benefit those people suffering from gastric cancer who are no longer treatable by any other therapies.
The research was conducted with 507 patients who were dealing with nonresectable metastatic gastric adenocarcinoma. Two different groups i.e. trifluridine/tipiracil group and placebo group was part of the research.
According to the David Cunningham, a consultant medical oncologist said, "We have nothing else we can offer those patients, and this study shows that we can extend life expectancy and improve disease control rates up to a very significant level."
Scientists have recommended the dose of Lonsurf orally about 35mg/m2/dose two times a day. The medication must be taken with food on day 1 through 5 and day 8 through 12 in the cycle of 28 days.
According to the researchers, this new treatment would meet the said needs of the patients.